STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences Inc - CSTL STOCK NEWS

Welcome to our dedicated news page for Castle Biosciences (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Castle Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Castle Biosciences's position in the market.

News
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 19, 2024. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
-
News
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces data presentations at AAD Annual Meeting showcasing improved survival in patients with cutaneous melanoma using DecisionDx-Melanoma test. The company's gene expression profile tests demonstrate effectiveness in guiding personalized care for skin cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
conferences
-
News
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces the largest study of its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma, demonstrating improved predictive accuracy and personalized treatment pathways. The study highlights the test's ability to guide risk-appropriate treatment decisions, reducing overtreatment and undertreatment, based on patients' biological risk of metastasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
News
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
Castle Biosciences (CSTL) reports a strong performance in 2023, with $220 million revenue, a 60% increase from 2022, and 70,429 test reports delivered. The company also achieved $243 million in cash, two critical publications associating with DecisionDx-Melanoma testing, and a successful conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.95%
Tags
earnings
-
News
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced study results demonstrating the superior risk stratification of DecisionDx-Melanoma in stage I melanoma patients. The study, including 5,651 patients, showed better outcomes than AJCC8 staging. Incorporating DecisionDx-Melanoma may enhance clinical decision-making for more precise information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
News
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. The company will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Access details for the webcast and phone conference call are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
News
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced a study in The Journal of Clinical and Aesthetic Dermatology which found that using its DecisionDx-SCC test to guide adjuvant radiation therapy (ART) decisions for patients with squamous cell carcinoma (SCC) could result in substantial Medicare healthcare savings of up to approximately $972 million annually. The study also highlighted the potential to improve patient care by providing added confidence in decisions to forgo radiation therapy when a patient’s risk of metastasis is low.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will present new data on its dermatologic gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference. The data includes real-world evidence confirming risk stratification for melanoma, identifying high-risk SCC patients, diagnostic discordance for melanocytic lesions, and gene expression differences in skin samples of inflammatory skin diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced that its COO, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. Oelschlager's extensive background and instrumental role in Castle's success have led to her recognition as a driving force in biotechnology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
none
News
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) expects to deliver total revenue of over $210 million in 2023, representing at least 53% growth over 2022. The company also anticipates cash, cash equivalents, and marketable investment securities to be approximately $243 million by the end of 2023. The preliminary, unaudited results for the fourth quarter and full year ended Dec. 31, 2023, show significant growth in test reports delivered, indicating a successful year for Castle Biosciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
earnings
Stock CSTL logo
Castle Biosciences Inc

Nasdaq:CSTL

CSTL Rankings

#2873 Ranked by Market Cap
#4637 Ranked by Stock Gains
N/A Ranked by Dividends

CSTL Stock Data

553.40M
26.64M
4.28%
89.75%
5.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Friendswood

About CSTL

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.